News
News Center
Baimeixing ® Bairui granule was listed in the "Chinese medicine brand list"
Release time:
2022-07-15 09:23
Source:
On July 14, 2022, the "2022 Chinese medicine brand list" hosted by micnet was officially released.
Jiuhua Huayuan Pharmaceutical baimeixing ® With its excellent market performance and brand influence, Bairui granule was listed on the list of cough relieving, phlegm resolving and asthma relieving drugs, the hospital terminal of the "Chinese medicine brand list", and became the focus of the industry.
This "China pharmaceutical brand list" is strictly selected from various brands according to the sales amount and growth rate of products at the three terminals in the past three years shown by the terminal monitoring data of "three terminals and six markets" (see the definition range in the figure below). All the brands that can be selected are outstanding in the category. It is reported that baimeixing ® It is the third time that Bairui granule has been listed, which reflects the market's interest in baimeixing ® Bairui granule's great recognition of brand strength is also the industry's recognition of baimeixing ® Affirmation of the position of Bairui granule industry.
Baimeixing ® Since its listing in 2009, Bairui granule has been intensively cultivated in optimizing the process, ensuring the quality and improving the dosage form, and has spared no effort to provide support for clinical medication. Jiuhua Huayuan Pharmaceutical has built it into a heavy gold single product through professional academic promotion. After years of development, baimeixing ® Bairui granule has become a leading brand in the respiratory field and entered the national medical insurance and national basic drug catalogue, building a healthy barrier for many patients with upper respiratory tract infection.
Brand is not only the presentation of enterprise value, but also the demonstration of product strength. Brand represents trust and responsibility. In order to alleviate the drug dilemma of children, the State encourages the secondary development of Chinese patent medicines that are safe for clinical use and the research and development of dosage forms for children. Jiuhua Huayuan Pharmaceutical has carried out phase III clinical trials on Bairui granule for children. In the future, Jiuhua Huayuan Pharmaceutical will give full play to its advantages, rise to difficulties, strive to make better products benefit more people, live up to the corporate mission of "serving and contributing to human health", and forge ahead on the road of serving human health.
Related News
2024-09-30
2024-09-30
